Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir
John N. Mafi, Sitaram Vangala, Moira K. Kapral, Peter E. Wu, Manying Cui, Artem Romanov, Katherine L. Kahn
Abstract
Randomized clinical trials of nirmatrelvir-ritonavir found reduced COVID-19–related hospitalizations among unvaccinated patients but not vaccinated patients. Although advanced age is the strongest predictor of severe COVID-19, the median ages of the trial participants were 42 and 46 years. It remains unknown whether the results of these trials generalize to older and highly vaccinated populations. We made use of a natural experiment to compare hospitalization and mortality outcomes in vaccinated older adults with vs without restricted access to nirmatrelvir-ritonavir.
Link (JAMA) [Paywall]
John N. Mafi, Sitaram Vangala, Moira K. Kapral, Peter E. Wu, Manying Cui, Artem Romanov, Katherine L. Kahn
Abstract
Randomized clinical trials of nirmatrelvir-ritonavir found reduced COVID-19–related hospitalizations among unvaccinated patients but not vaccinated patients. Although advanced age is the strongest predictor of severe COVID-19, the median ages of the trial participants were 42 and 46 years. It remains unknown whether the results of these trials generalize to older and highly vaccinated populations. We made use of a natural experiment to compare hospitalization and mortality outcomes in vaccinated older adults with vs without restricted access to nirmatrelvir-ritonavir.
Link (JAMA) [Paywall]